首页> 外文期刊>Prostaglandins, Leukotrienes, and Essential Fatty Acids >Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes
【24h】

Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes

机译:在人肝微粒体和重组UDP-葡糖醛糖基转移酶的非甾体抗炎药物中抑制20-羟基辛二酮酸(20-HETE)葡糖醛酸化

获取原文
获取原文并翻译 | 示例
           

摘要

20-hydroxyeicosatetraenoic acid (20-HETE) is an arachidonic acid metabolite which is known to increase platelet aggregation and cardiovascular risk. In this study, nine non-steroidal anti-inflammatory drugs (NSAIDs) selected by chemical structures were screened to determine their effects on the glucuronidation of 20-HETE using human liver microsomes (HLMs). Then, the combined effects of the selected NSAID and genetic polymorphisms in UDP-glucuronosyltransferase (UGT) were investigated. Among the tested NSAIDs, diclofenac was the strongest inhibitor of 20-HETE glucuronidation with an IC50 value of 3.5 mu M. Celecoxib, naproxen, mefenamic acid, ibuprofen, and indomethacin showed modest inhibition with IC50 values of 77, 91, 190, 208, and 220 mu M. respectively, while acetylsalicylic acid, rofecoxib, and meloxicam did not inhibit 20-HETE glucuronidation. Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). In addition, diclofenac exhibited a competitive inhibition mechanism with the K-m value of 20-HETE glucuronidation increasing from 23.5 mu M to 62 mu M in the presence of 3.5 mu M diclofenac. Diclofenac further decreased 20-HETE glucuronidation in HLMs carrying UGT2B7*2 alleles compared with the wild-type HLMs. The results from this study would be useful in understanding the alteration of 20-HETE levels in relation to NSAID and UGT genetic polymorphisms.
机译:20-羟基辛苷(20-HETE)是一种众所周知的花生酸代谢物,可提高血小板聚集和心血管风险。在本研究中,筛选通过化学结构选择的九个非甾体抗炎药(NSAIDs)以确定它们对使用人肝微粒体(HLM)20-HETE的葡糖醛酸化的影响。然后,研究了所选NSAID和遗传多态性在UDP-葡糖糖核糖基亚糖苷酶(UGT)中的组合效应。在测试的NSAID中,Diclofenac是20-HETE葡萄糖醛化的最强抑制剂,IC50值为3.5μm。塞克西布,萘普生,梅芬酸,布洛芬和吲哚美辛表现出适度的抑制作用,IC50值为77,91,190,208,分别为220亩,同时乙酰山酸,罗法氧化和美洛昔康未抑制20-HETE葡糖醛酸化。通过UGT2B7和UGT1A9重组酶20-HETE的葡萄糖醛酸化由吲哚美辛,Mefanemic酸,双氯芬酸,布洛芬,萘普生和Celecoxib(P <0.001)显着抑制了UGT2B7和UGT1A9重组酶。此外,双氯芬酸表现出竞争性抑制机制,其20-HETE血糖醛酸的K-M值在3.5μmdiClofenac存在下从23.5μm至62μm增加。与野生型HLM相比,双氯芬酸进一步降低了携带UGT2B7 * 2等位基因的HLMS中的20-HETE葡糖醛酸。该研究的结果对于了解与NSAID和UGT遗传多态性有关的20-HETE水平的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号